FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385230916> ?p ?o ?g. }

• W4385230916 abstract "Introduction Drug interactions constitute a significant issue in cancer treatment. Therefore, it is important to assess and analyze all cancer patients’ therapies prior to the initiation of chemotherapy. Methods A retrospective observational study was conducted at the Near East University Hospital Oncology Department located in North Cyprus between June 2019 and December 2021. The aim of the study was to determine the nature, type, and frequency of potential drug–drug interactions in breast cancer patients receiving a doxorubicin and cyclophosphamide regimen using Drugs.com, Lexicomp, and Micromedex databases while comparing the three electronic databases, according to the frequency, mechanism, and severity of drug–drug interactions. Results The study included 40 patients (44.4%) out of 90 patients diagnosed with breast cancer, as 50 patients (55.6%) who did not match the criteria were excluded. According to the Lexicomp database, 12 patients (30%) with breast cancer had 14 potential drug–drug interactions, according to the Drugs.com database, 15 patients (37.5%) with breast cancer had 22 potential drug–drug interactions, and according to the Micromedex database, 13 patients (32.5%) with breast cancer had 15 potential drug–drug interactions. Pearson correlation indicated a weak association (Lexicomp: r = 0.475, p = 0.002 and Micromedex: r = 0.491, p = 0.001) and a moderate association (Drugs.com: r = 0.500, p = 0.001) between potential drug–drug interactions and five or more medications. Conclusion This study showed that the Drugs.com database detected more potential drug interactions between chemotherapy and nonchemotherapy than the Lexicomp and Micromedex databases. Comprehensive drug review, use of electronic health record systems, and collaboration between healthcare providers such as pharmacists and physicians may be necessary strategies to minimize potential drug–drug interactions and optimize cancer treatment in patients with breast cancer." @default.
• W4385230916 created "2023-07-26" @default.
• W4385230916 creator A5020167917 @default.
• W4385230916 creator A5074236066 @default.
• W4385230916 creator A5083895712 @default.
• W4385230916 date "2023-07-24" @default.
• W4385230916 modified "2023-09-27" @default.
• W4385230916 title "Determination of drug–drug interaction in breast cancer patients receiving doxorubicin and cyclophosphamide regimen" @default.
• W4385230916 cites W1756028908 @default.
• W4385230916 cites W1865977567 @default.
• W4385230916 cites W1969916873 @default.
• W4385230916 cites W2091415346 @default.
• W4385230916 cites W2121505997 @default.
• W4385230916 cites W2121823208 @default.
• W4385230916 cites W2605525329 @default.
• W4385230916 cites W2908938827 @default.
• W4385230916 cites W2997743675 @default.
• W4385230916 cites W3126338203 @default.
• W4385230916 cites W4225508645 @default.
• W4385230916 doi "https://doi.org/10.1177/10781552231189700" @default.
• W4385230916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37489038" @default.
• W4385230916 hasPublicationYear "2023" @default.
• W4385230916 type Work @default.
• W4385230916 citedByCount "0" @default.
• W4385230916 crossrefType "journal-article" @default.
• W4385230916 hasAuthorship W4385230916A5020167917 @default.
• W4385230916 hasAuthorship W4385230916A5074236066 @default.
• W4385230916 hasAuthorship W4385230916A5083895712 @default.
• W4385230916 hasConcept C121608353 @default.
• W4385230916 hasConcept C126322002 @default.
• W4385230916 hasConcept C143998085 @default.
• W4385230916 hasConcept C2776694085 @default.
• W4385230916 hasConcept C2776755627 @default.
• W4385230916 hasConcept C2780035454 @default.
• W4385230916 hasConcept C2781413609 @default.
• W4385230916 hasConcept C530470458 @default.
• W4385230916 hasConcept C71924100 @default.
• W4385230916 hasConcept C98274493 @default.
• W4385230916 hasConceptScore W4385230916C121608353 @default.
• W4385230916 hasConceptScore W4385230916C126322002 @default.
• W4385230916 hasConceptScore W4385230916C143998085 @default.
• W4385230916 hasConceptScore W4385230916C2776694085 @default.
• W4385230916 hasConceptScore W4385230916C2776755627 @default.
• W4385230916 hasConceptScore W4385230916C2780035454 @default.
• W4385230916 hasConceptScore W4385230916C2781413609 @default.
• W4385230916 hasConceptScore W4385230916C530470458 @default.
• W4385230916 hasConceptScore W4385230916C71924100 @default.
• W4385230916 hasConceptScore W4385230916C98274493 @default.
• W4385230916 hasLocation W43852309161 @default.
• W4385230916 hasLocation W43852309162 @default.
• W4385230916 hasOpenAccess W4385230916 @default.
• W4385230916 hasPrimaryLocation W43852309161 @default.
• W4385230916 hasRelatedWork W2354833489 @default.
• W4385230916 hasRelatedWork W2365277249 @default.
• W4385230916 hasRelatedWork W2367105124 @default.
• W4385230916 hasRelatedWork W2376107280 @default.
• W4385230916 hasRelatedWork W2379009234 @default.
• W4385230916 hasRelatedWork W2380201224 @default.
• W4385230916 hasRelatedWork W2388730008 @default.
• W4385230916 hasRelatedWork W2791179561 @default.
• W4385230916 hasRelatedWork W4214554217 @default.
• W4385230916 hasRelatedWork W64123703 @default.
• W4385230916 isParatext "false" @default.
• W4385230916 isRetracted "false" @default.
• W4385230916 workType "article" @default.